Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs

Clinical trial NCT00137917 · COMPLETED

Trial details

NCT number: NCT00137917
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Infections, Meningococcal

Start date: 2002-07-01
Primary completion: 2003-06-01
Enrollment: 478

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.